Printer Friendly

Chiron Makes Genital Herpes Vaccine Announcement.

EMERYVILLE, Calif.--(BUSINESS WIRE)--Nov. 25, 1996--Chiron Corp. (NASDAQ: CHIR) announced today that its preliminary analysis of data available from prophylactic genital herpes vaccine trials conducted by its Chiron Vaccines business unit does not indicate efficacy for the product. Based upon these results, the company does not intend to pursue a Product License Application (PLA) for this product. Further analysis of the data is underway. Complete results will be reported by clinical investigators in appropriate scientific forums.

Chiron Corp., headquartered in Emeryville, near San Francisco, is a science-driven healthcare company that combines diagnostic, vaccine and therapeutic strategies for controlling disease. Chiron participates in four global markets: diagnostics, including immunodiagnostics, critical care diagnostics, and new quantitative probe tests; pediatric and adult vaccines; therapeutics, with an emphasis on oncology and infectious diseases; and ophthalmic surgical products for the correction of vision.

Chiron also has research programs underway in gene therapy and gene transfer, combinatorial transfer, combinatorial chemistry, cardiovascular disease and critical care. Chiron had total revenues of $1.1 billion for the year ended Dec. 31, 1995.

CONTACT: Chiron Corp., Emeryville

Larry Kurtz, 510/923-2476
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 25, 1996
Words:183
Previous Article:Paradigm Technology, Inc. Announces Completion of Workforce Reductions.
Next Article:Zila Hires Brad Anderson as Vice President - Treasurer.
Topics:


Related Articles
Herpes battle flurries.
Herpes gets in your eyes.
Therapeutic vaccine fights herpes.
DNA vaccine immunizes fetal lambs.
Suppressive drug therapy hinders herpes. (Biomedicine).
STRESSGEN/ROCHE TO DEVELOP/MARKET HPV VACCINE.
Herpes vaccine progresses. (Immunology).
One-two punch vaccine fights herpes with antibodies, T cells.
CHIRON GETS PANDEMIC INFLUENZA VACCINE CONTRACT WITH U.K.
Gellin' against herpes and HIV.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters